| Quarterly Financials | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 0 | 682 | 1,145 | 1,224 | 1,292 | 1,285 | 1,170 | 1,306 | 1,160 | 1,139 | 1,077 | 1,020 | 969 | 1,070 | 1,020 | 1,040 | 1,056 | 1,047 | 1,041 | 1,121 |
| Expenses | 0 | 580 | 863 | 1,027 | 1,074 | 1,153 | 1,025 | 1,151 | 1,007 | 1,043 | 959 | 902 | 871 | 983 | 915 | 921 | 919 | 905 | 896 | 985 |
| EBITDA | 0 | 102 | 281 | 197 | 219 | 132 | 145 | 156 | 153 | 96 | 119 | 118 | 98 | 87 | 105 | 119 | 137 | 142 | 145 | 135 |
| Operating Profit % | 0 % | 15 % | 24 % | 16 % | 16 % | 10 % | 12 % | 11 % | 13 % | 8 % | 10 % | 11 % | 9 % | 7 % | 9 % | 11 % | 12 % | 13 % | 13 % | 11 % |
| Depreciation | 0 | 22 | 32 | 31 | 30 | 31 | 31 | 31 | 30 | 30 | 32 | 34 | 34 | 36 | 39 | 40 | 40 | 39 | 41 | 41 |
| Interest | 0 | 7 | 13 | 7 | 5 | 6 | 4 | 5 | 7 | 6 | 12 | 13 | 15 | 14 | 14 | 15 | 12 | 14 | 13 | 12 |
| Profit Before Tax | 0 | 77 | 243 | 165 | 187 | 115 | 116 | 124 | 122 | 76 | 81 | 80 | 55 | 51 | 66 | 80 | 96 | 102 | 100 | 93 |
| Tax | 0 | 23 | 75 | 54 | 58 | 46 | 36 | 40 | 30 | 23 | 24 | 22 | 17 | 22 | 17 | 21 | 26 | 28 | 25 | 23 |
| Net Profit | 0 | 54 | 168 | 111 | 129 | 69 | 79 | 84 | 92 | 52 | 58 | 58 | 39 | 29 | 49 | 59 | 69 | 74 | 75 | 70 |
| EPS in ₹ | 0.00 | 5.20 | 10.58 | 6.97 | 8.12 | 4.31 | 4.99 | 5.31 | 5.75 | 3.29 | 3.63 | 3.64 | 2.44 | 1.85 | 3.08 | 3.73 | 4.39 | 4.69 | 4.75 | 4.40 |
Jubilant Ingrevia
Jubilant Ingrevia
719.75
-4.50
(-0.62%)
Key Fundamentals
Market Cap
11,464.26 Cr
EPS
15.89
PE Ratio
39.96
Dividend Yield
0.69 %
Industry
Chemicals 52 Week High
885.00
52 Week Low
535.20
PB Ratio
3.78
Debt to Equity
0.27
Sector
Specialty Chemicals Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Jubilant Ingrevia Limited successfully redeemed its Rs. 50 crore commercial paper (ISIN-INEOBY014425) on November 21, 2025, which was the scheduled maturity date. The commercial paper was originally issued on September 25, 2025, and the company has fulfilled its debt obligation as planned.
Jubilant Ingrevia achieved revenue of Rs 1,121 crores in Q2FY26 with 8% YoY growth, driven by strong performance in Specialty Chemicals segment and highest quarterly sales volumes in Chemical Intermediates over the last six quarters. The company's EBITDA grew 8% YoY to Rs 146 crores while Profit After Tax surged 18% YoY to Rs 70 crores, supported by volume expansion across CDMO, Fine Chemicals, and Acetyls business despite pricing pressures in some segments.
Jubilant Ingrevia Reports 8% EBITDA Growth in Q2FY26 with Strong Performance in Specialty Chemicals
Nov 10, 2025
Nov 10, 2025Jubilant Ingrevia Limited announced quarterly results showing 8% year-over-year EBITDA growth and 18% increase in Profit After Tax. The company's Specialty Chemicals segment drove growth momentum with double-digit revenue growth and maintained 25% margins during the quarter. The Nutrition business recorded steady volume growth across core products, while Chemical Intermediates business achieved highest quarterly sales in the last six quarters. Revenue grew 7% year-over-year to Rs 1,121 crore. On a half-yearly basis, EBITDA grew 18% and Profit After Tax surged 34%. The company successfully delivered volumes against a new Agro CDMO innovator contract and added 104 new molecules in their CDMO/Fine chemicals portfolio. Management expects continued growth momentum in H2FY26, fueled by progress in Specialty Chemicals and Nutrition businesses, with a major CDMO order expected to start in early 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,472.10 | #1 1,49,817.68 | 67.45 | 13,387.50 | 6.91 | #1 2,096 | 8.20 | 46.78 | |
2,838.40 | 84,137.22 | 52.26 | 14,825.80 | 12.13 | 1,251 | 92.75 | 39.23 | |
3,481.10 | 38,239.88 | 56.35 | 4,853.20 | 10.61 | 546 | 47.93 | 40.03 | |
5,973.00 | 30,585.21 | 68.99 | 2,393.10 | 12.83 | 289 | #1 152.38 | 71.53 | |
1,691.80 | 23,074.97 | 43.74 | 8,365.80 | 7.84 | 697 | -38.83 | 32.43 | |
440.55 | 21,756.54 | 34.54 | 4,664.30 | 10.33 | 555 | 29.77 | 34.47 | |
4,395.30 | 19,025.34 | 50.39 | #1 15,339.40 | 10.81 | 479 | -16.18 | 44.40 | |
5,971.00 | 17,579.67 | #1 31.74 | 5,692.40 | #1 18.99 | 499 | 30.75 | 50.57 | |
1,594.60 | 16,530.52 | 38.55 | 2,292.50 | 18.24 | 405 | 10.06 | 32.55 | |
1,246.80 | 14,194.61 | 60.16 | 1,448.50 | -3.77 | 160 | 86.93 | 80.27 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
1.06 %
Net Income Growth
37.34 %
Cash Flow Change
18.17 %
ROE
28.44 %
ROCE
18.41 %
EBITDA Margin (Avg.)
20.75 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 0 | 3,379 | 3,797 | 4,259 | 4,732 | 5,032 |
| Fixed Assets | 0 | 1,805 | 1,798 | 1,846 | 2,539 | 2,581 |
| Current Assets | 0 | 1,424 | 1,765 | 1,818 | 1,780 | 1,853 |
| Capital Work in Progress | 0 | 65 | 174 | 525 | 331 | 525 |
| Investments | 0 | 50 | 6 | 8 | 16 | 37 |
| Other Assets | 0 | 1,458 | 1,819 | 1,880 | 1,846 | 1,889 |
| Total Liabilities | 0 | 3,379 | 3,797 | 4,259 | 4,732 | 5,032 |
| Current Liabilities | 0 | 894 | 1,053 | 1,180 | 1,286 | 1,401 |
| Non Current Liabilities | 0 | 561 | 311 | 413 | 708 | 704 |
| Total Equity | -0 | 1,923 | 2,433 | 2,666 | 2,738 | 2,927 |
| Reserve & Surplus | -0 | 1,907 | 2,417 | 2,650 | 2,722 | 2,911 |
| Share Capital | 0 | 16 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 73 | -36 | 35 | 6 | -9 |
| Investing Activities | 0 | 33 | -71 | -469 | -568 | -389 |
| Operating Activities | 0 | 112 | 453 | 463 | 430 | 508 |
| Financing Activities | 0 | -72 | -418 | 42 | 144 | -129 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 50.68 % | 50.92 % | 50.92 % | 51.03 % | 51.10 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 51.47 % | 45.22 % | 45.22 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 6.35 % | 6.58 % | 6.55 % | 7.22 % | 6.89 % | 7.12 % | 6.96 % | 5.96 % |
| DIIs | 0.83 % | 0.96 % | 0.32 % | 0.14 % | 0.15 % | 0.17 % | 1.38 % | 4.90 % | 5.98 % | 6.73 % | 8.21 % | 11.18 % | 13.61 % | 14.09 % | 15.47 % | 15.99 % | 15.92 % | 21.80 % | 23.04 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.02 % |
| Public / Retail | 16.76 % | 21.30 % | 27.18 % | 26.23 % | 27.31 % | 27.61 % | 26.71 % | 25.75 % | 25.72 % | 26.13 % | 24.11 % | 22.74 % | 20.63 % | 20.57 % | 19.47 % | 19.17 % | 19.13 % | 19.41 % | 19.20 % |
| Others | 31.74 % | 26.82 % | 21.58 % | 22.60 % | 21.43 % | 20.75 % | 20.44 % | 17.87 % | 16.83 % | 15.66 % | 16.20 % | 8.26 % | 7.71 % | 7.32 % | 6.36 % | 6.47 % | 6.36 % | 6.60 % | 6.56 % |
| No of Share Holders | 60,038 | 95,235 | 1,49,939 | 1,81,847 | 1,91,477 | 1,93,858 | 1,95,704 | 1,86,895 | 1,85,062 | 1,86,294 | 1,73,533 | 1,62,202 | 1,50,388 | 1,42,736 | 1,25,367 | 1,24,830 | 1,20,406 | 1,23,748 | 1,25,749 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 5 | 5 | 5 | 5 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 1.39 | 1.1 | 0.77 | 0.69 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 01 Feb 2021 |  Change Of Name | NA | 01 Feb 2021 | 0.00 | 0.00 |
| 06 Aug 2021 |  Dividend | ₹ 0.35 /share | 05 Aug 2021 | 571.85 | 610.15 |
| 11 Feb 2022 | Dividend | ₹ 2.50 /share | 10 Feb 2022 | 572.25 | 567.85 |
| 24 Aug 2022 | Dividend | ₹ 2.50 /share | 23 Aug 2022 | 464.15 | 476.15 |
| 10 Feb 2023 | Dividend | ₹ 2.50 /share | 10 Feb 2023 | 472.90 | 472.65 |
| 10 Aug 2023 | Dividend | ₹ 2.50 /share | 10 Aug 2023 | 422.00 | 433.05 |
| 09 Feb 2024 | Dividend | ₹ 2.50 /share | 09 Feb 2024 | 460.65 | 436.55 |
| 02 Aug 2024 | Dividend | ₹ 2.50 /share | 02 Aug 2024 | 519.65 | 612.55 |
| 30 Aug 2024 |  Annual General Meeting | NA | 30 Aug 2024 | 610.10 | 642.85 |
| 22 Oct 2024 |  Quarterly Result Announcement | NA | 22 Oct 2024 | 732.20 | 731.40 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 711.10 | 659.30 |
| 03 Feb 2025 | Dividend | ₹ 2.50 /share | 03 Feb 2025 | 659.30 | 697.65 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 696.10 | 718.00 |
| 25 Jul 2025 | Dividend | ₹ 2.50 /share | 25 Jul 2025 | 718.00 | 819.20 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 818.85 | 810.60 |
| 29 Aug 2025 | Annual General Meeting | NA | 29 Aug 2025 | 754.40 | 727.55 |
| 27 Oct 2025 | Quarterly Result Announcement | NA | 27 Oct 2025 | 650.85 | 677.70 |
Announcements
Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024 As Amended1 day ago
1 day agoIntimation of Repayment of Commercial Paper (CP)1 day ago
1 day agoIntimation of Repayment of Commercial Paper (CP)1 day ago
1 day agoNewspaper Advertisement - Public Notice Regarding Loss Of Share Certificates3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 27, 2025
Oct 27, 2025Grant Of Options/ Restricted Stock Units (Rsus) Under Jubilant Ingrevia Employees Stock Option Plan 2021Oct 27, 2025
Oct 27, 2025Unaudited Financial Results For Quarter And Half Year Ended 30 September 2025Oct 27, 2025
Oct 27, 2025Unaudited Financial Results For Quarter And Half Year Ended 30 September 2025Oct 27, 2025
Oct 27, 2025Board Meeting Outcome for Meeting Held On October 27 2025Oct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 13, 2025
Oct 13, 2025Board Meeting Intimation for Adoption Of Unaudited Half Yearly Results As On September 30 2025Oct 13, 2025
Oct 13, 2025Commercial Paper Proceeds Utilisation Certificate For The Quarter Ended September 30 2025Oct 10, 2025
Oct 10, 2025Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign"Oct 10, 2025
Oct 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowOct 01, 2025
Oct 01, 2025Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024 As AmendedSep 25, 2025
Sep 25, 2025Intimation of Repayment of Commercial Paper (CP)Sep 25, 2025
Sep 25, 2025Intimation Of Record Date For Maturity Of Commercial PaperSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesSep 22, 2025
Sep 22, 2025Intimation Of Record Date For Maturity Of Commercial PaperSep 22, 2025
Sep 22, 2025Intimation of Repayment of Commercial Paper (CP)Sep 16, 2025
Sep 16, 2025Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024 As AmendedSep 16, 2025
Sep 16, 2025Intimation of Repayment of Commercial Paper (CP)Sep 15, 2025
Sep 15, 2025Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024 As AmendedSep 15, 2025
Sep 15, 2025Appointment And Re-Appointment Of Directors Statutory Auditors And Secretarial AuditorsAug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 29, 2025
Aug 29, 2025Appointment And Re-Appointment Of Directors Statutory Auditors And Secretarial AuditorsAug 29, 2025
Aug 29, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 29, 2025
Aug 29, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 29, 2025
Aug 29, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 19, 2025
Aug 19, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 19, 2025
Aug 19, 2025Intimation Of Record Date For Maturity Of Commercial PapersAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Credit RatingAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesAug 11, 2025
Aug 11, 2025E-Mail To Shareholders Intimating About Deduction Of Tax At Source (TDS) On Final Dividend For FY 2024-25Aug 07, 2025
Aug 07, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Transcript Of The Investors Conference
Call For The Quarter Ended June 30 2025Aug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Aug 06, 2025Intimation Regarding Letter Dispatched To The Shareholders Of The Company For Annual Report Of The Company For FY 2024-25Aug 06, 2025
Aug 06, 2025Notice Of 6Th Annual General Meeting Along With Annual Report For The Financial Year 2024-25Aug 05, 2025
Aug 05, 2025Reg. 34 (1) Annual Report.Aug 05, 2025
Aug 05, 2025Notice Of 6Th Annual General Meeting Along With The Annual Report For The Financial Year 2024-25Aug 05, 2025
Aug 05, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 05, 2025
Aug 05, 2025Mutual Fund Holdings
Bandhan Large & Mid Cap Fund Direct-Growth 
Axis Business Cycles Fund Direct-Growth 
Kotak Small Cap Fund Direct-Growth 
DSP Top 100 Equity Direct Plan-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
HDFC Manufacturing Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty 500 Index Fund Direct-Growth 
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 60.88
ATR(14)
Less Volatile 22.00
STOCH(9,6)
Overbought 86.63
STOCH RSI(14)
Overbought 92.99
MACD(12,26)
Bullish 5.46
ADX(14)
Weak Trend 17.93
UO(9)
Bearish 62.49
ROC(12)
Uptrend And Accelerating 4.23
WillR(14)
Overbought -7.60
About Jubilant Ingrevia
Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider. Incorporated in 2019, the company serves Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It operates through three core segments: Speciality Chemicals, Nutrition and Health Solutions, and Life Science Chemicals. The company manufactures and supplies speciality intermediates, nutrition & health solutions, and life science chemicals through five facilities in India. Jubilant Ingrevia is the global largest producer of Niacinamide and among the top two manufacturers of Vitamin B3 globally. It serves over 1400 customers in more than 60 countries and offers custom research and manufacturing services. The company is part of the Jubilant Bhartia Group and became a separate entity following a demerger from Jubilant Pharmova Limited in 2021.
Chairperson NameShyam S Bhartia
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
